Hao Chen | Biomedicine | Best Researcher Award

Posted on by ScienceFather

Prof. Hao Chen | Biomedicine | Best Researcher Award

Associate Professor, Chief Physician, Supervisor at Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China

Summary:

Prof. Hao Chen is an accomplished Associate Professor and Chief Physician of Neurosurgery at Shanghai Jiao Tong University School of Medicine, where he also serves as a graduate supervisor. He holds a Doctor of Medicine degree from the same institution and specializes in traumatic brain injury, stroke, and neurocritical care. His research interests include neuromodulation, brain-computer interfaces, and the integration of artificial intelligence in neurosurgery. Prof. Chen has received significant funding for his research, including grants from the National Natural Science Foundation of China. He has been recognized with several awards, including the “Wang Kuancheng” Medical Award and the AANS/CNS BrainLab Neurosurgery Award. Additionally, he is a visiting assistant professor at Vanderbilt University Medical Center and actively participates in professional organizations, contributing to advancements in neurosurgery and medical education. His work has been widely published in leading journals, underscoring his impact in the field.

Profile:

Education:

Prof. Hao Chen completed his Doctor of Medicine at Shanghai Jiao Tong University School of Medicine from September 2013 to July 2017. Prior to this, he earned his Master of Medicine from the same institution between September 2005 and July 2008. His academic journey began at Qingdao University School of Medicine, where he obtained his Bachelor of Clinical Medicine, graduating in July 2005. This comprehensive educational background has equipped him with a strong foundation in medical sciences, particularly in the field of neurosurgery.

Professional Experience:

Prof. Hao Chen has an extensive professional background in neurosurgery and medical education. Currently serving as an Associate Professor and Chief Physician of Neurosurgery at Shanghai Jiao Tong University School of Medicine, he also acts as a graduate supervisor and Vice Director of the Clinical Diagnosis and Treatment Center for Traumatic Brain Injury and Neurocritical Care. In addition to his primary role, Prof. Chen is a visiting assistant professor at Vanderbilt University Medical Center, where he collaborates on advanced research initiatives. He is actively involved in various professional committees, including the Peripheral Nerve Professional Committee of the Chinese Medical Doctor Association, and holds memberships in the American Congress of Neurological Surgeons and the International Brain Injury Association. His clinical expertise encompasses traumatic brain injury, intracerebral hemorrhage, glioblastoma, and neurosurgical intensive care, further demonstrating his commitment to improving patient outcomes and advancing the field of neurosurgery.

Research Interests:

Prof. Hao Chen’s research interests lie at the intersection of neurosurgery and advanced medical technologies. His primary focus includes traumatic brain injury (TBI), stroke, and neurocritical care, where he explores innovative approaches to improve patient management and recovery. He is particularly interested in neuromodulation techniques and the development of brain-computer interfaces that can enhance neurorehabilitation. Additionally, Prof. Chen is actively engaged in integrating artificial intelligence technologies into neurosurgery, aiming to optimize surgical outcomes and refine diagnostic processes. His work seeks to uncover the underlying mechanisms of neurological injuries and develop targeted therapeutic strategies, making significant contributions to the field of neurosurgical research and clinical practice.

Skills:

Prof. Hao Chen possesses a diverse array of skills that are integral to his role as a neurosurgeon and researcher. His clinical expertise encompasses advanced surgical techniques for managing traumatic brain injuries, intracerebral hemorrhages, and glioblastomas, ensuring optimal patient care in high-stakes environments. He is proficient in the application of neurocritical care protocols, emphasizing the importance of comprehensive patient management. In addition to his surgical acumen, Prof. Chen is skilled in utilizing neuromodulation therapies and brain-computer interfaces, showcasing his commitment to integrating innovative technologies into clinical practice. His research capabilities are bolstered by a strong foundation in grant writing, data analysis, and the implementation of clinical trials, enabling him to contribute effectively to the advancement of neurosurgical science and education. Furthermore, his collaborative spirit and leadership qualities foster interdisciplinary teamwork, essential for tackling complex medical challenges.

Conclution:

Prof. Hao Chen’s extensive educational background, current research focus on neurosurgery, substantial funding and awards, active participation in clinical trials, and impactful publications collectively position him as an outstanding candidate for the Research for Best Researcher Award. His dedication to advancing the field of neurosurgery through innovative research and clinical practices significantly contributes to improving patient outcomes and the broader scientific community.

Publication Top Noted:

  • Transplantation of Astrocyte-Derived Mitochondria into Injured Astrocytes Has a Protective Effect Following Stretch Injury
    Authors: Q.-Y. Gong, W. Wang, L. Cai, H. Chen, Z.-M. Xu
    Journal: Mitochondrion
    Volume: 78
    Article Number: 101902
    Year: 2024
  • Endorepellin Downregulation Promotes Angiogenesis After Experimental Traumatic Brain Injury
    Authors: Q. Zhang, Y. Jing, Q. Gong, J. Ding, Z. Xu
    Journal: Neural Regeneration Research
    Volume: 19(5)
    Pages: 1092–1097
    Year: 2024
  • MiR-181b Promotes Angiogenesis and Neurological Function Recovery After Ischemic Stroke
    Authors: L.-X. Xue, L.-Y. Shu, H.-M. Wang, Y.-W. Zhao, H. Chen
    Journal: Neural Regeneration Research
    Volume: 18(9)
    Pages: 1983–1989
    Year: 2023
    Cited by: 5
  • Inhibiting Phosphatase and Actin Regulator 1 Expression is Neuroprotective in the Context of Traumatic Brain Injury
    Authors: Y. Jing, L. Zhang, S.-W. Chen, Z.-M. Xu, J. Ding
    Journal: Neural Regeneration Research
    Volume: 18(7)
    Pages: 1578–1583
    Year: 2023
  • Glucose-Decorated Engineering Platelets for Active and Precise Tumor-Targeted Drug Delivery
    Authors: J. Zhao, Y. Shi, L. Xue, H. Chen, M. Kong
    Journal: Biomaterials Science
    Volume: 11(11)
    Pages: 3965–3975
    Year: 2023
    Cited by: 1
  • Knockout of Sirt2 Alleviates Traumatic Brain Injury in Mice
    Authors: W. Wang, Q.-Y. Gong, L. Cai, H. Chen, H.-L. Tian
    Journal: Neural Regeneration Research
    Volume: 18(2)
    Pages: 350–356
    Year: 2023
    Cited by: 7
  • ACT001 Attenuates Microglia-Mediated Neuroinflammation After Traumatic Brain Injury via Inhibiting AKT/NFκB/NLRP3 Pathway
    Authors: L. Cai, Q. Gong, L. Qi, H. Chen, H. Tian
    Journal: Cell Communication and Signaling
    Volume: 20(1), Article 56
    Year: 2022
    Cited by: 46
  • In Situ Injectable Nano-Complexed Hydrogel Based on Chitosan/Dextran for Combining Tumor Therapy via Hypoxia Alleviation and TAMs Polarity Regulation
    Authors: W. Zhang, Y. Shi, H. Li, H. Chen, M. Kong
    Journal: Carbohydrate Polymers
    Volume: 288
    Article Number: 119418
    Year: 2022
    Cited by: 22
  • Upregulation of C Terminus of Hsc70-Interacting Protein Attenuates Apoptosis and Procoagulant Activity and Facilitates Brain Repair After Traumatic Brain Injury (Retracted)
    Authors: H. Chen, Y. Jing, Z. Xu, H. Tian, L. Xue
    Journal: Frontiers in Neuroscience
    Volume: 14, Article 925
    Year: 2020
    Cited by: 4
  • A Brain-Penetrating Hsp90 Inhibitor NXD30001 Inhibits Glioblastoma as a Monotherapy or in Combination With Radiation
    Authors: H. Chen, Y. Gong, Y. Ma, Z. Cheng, L. Xue
    Journal: Frontiers in Pharmacology
    Volume: 11, Article 974
    Year: 2020
    Cited by: 15

Guodong Liang | Medicinal | Young Scientist Award

Posted on by ScienceFather

Assoc Prof Dr. Guodong Liang | Medicinal | Young Scientist Award

Senior Engineer at Inner Mongolia Medical University, China

Summary:

Assoc Prof Dr Guodong Liang is a senior engineer and master tutor at the College of Pharmacy, Inner Mongolia Medical University. Specializing in peptide-based antiviral research, Dr. Liang completed his Bachelor’s and Master’s degrees at Shenyang Pharmaceutical University in 2012 and 2015, respectively, and earned his Ph.D. from the Beijing Institute of Pharmacology and Toxicology in 2018. His research focuses on innovative peptide fusion inhibitors for treating viral infections, including HIV-1 and SARS-CoV-2. Notable for his contributions to peptide science, Dr. Liang has published extensively, holds a U.S. patent, and has received funding from various prestigious programs.

 

Profile:

Education:

Assoc Prof Dr Guodong Liang earned his Bachelor’s degree in Pharmacy from Shenyang Pharmaceutical University in 2012. He continued his studies at the same institution, obtaining a Master’s degree in Pharmaceutical Sciences in 2015. Further advancing his academic career, he completed his Ph.D. in Pharmacology and Toxicology at the Beijing Institute of Pharmacology and Toxicology in 2018. His educational background has provided a strong foundation for his research in peptide-based antiviral strategies.

Professional Experience:

Assoc Prof Dr Guodong Liang is a senior engineer and master tutor at the College of Pharmacy, Inner Mongolia Medical University. In this role, he leads research and teaching initiatives, focusing on peptide-based antiviral therapies. Prior to his current position, Dr. Liang has accumulated extensive experience in peptide research and development. His expertise encompasses the design of peptide fusion inhibitors and contributions to significant research projects funded by various programs, including the Inner Mongolia Natural Science Foundation and Inner Mongolia Medical University. His professional background reflects a commitment to advancing antiviral research and educating the next generation of scientists.

Research Interests:

Assoc Prof Dr Guodong Liang’s research interests are centered around peptide-based antiviral therapies. His work primarily focuses on the development and application of peptide fusion inhibitors to combat viral infections. Notable areas of his research include the design of isopeptide bond bundling superhelixes and their application in creating inhibitors against viruses such as HIV-1 and SARS-CoV-2. Dr. Liang explores innovative methods for developing broad-spectrum antiviral peptide drugs, aiming to enhance the efficacy of treatments for various viral diseases. His research integrates advanced peptide chemistry with practical antiviral applications, contributing to the field of pharmaceutical science.

Skills:

Assoc Prof Dr Guodong Liang possesses a robust skill set in peptide chemistry and antiviral drug development. His expertise includes designing and synthesizing peptide-based fusion inhibitors, with a focus on creating isopeptide bond bundling superhelixes for antiviral applications. Dr. Liang is proficient in advanced techniques for peptide analysis and evaluation, including structural and functional assessments of peptide interactions with viral proteins. His skills extend to securing and managing research funding, conducting collaborative projects, and publishing high-impact scientific papers. With a strong foundation in pharmacology and toxicology, Dr. Liang effectively translates complex scientific concepts into practical antiviral solutions.

Conclution:

Dr. Liang’s pioneering work in peptide-based antiviral research, evidenced by his impactful publications, patents, and innovative projects, demonstrates his significant contributions to the field. His research not only advances the design of targeted antiviral therapies but also lays the groundwork for developing broad-spectrum antiviral drugs, marking him as a leading candidate for the Research for Young Scientist Award.

Publication Tob Noted:

A small molecule compound targeting hemagglutinin inhibits influenza A virus and exhibits broad-spectrum antiviral activity

  • Authors: Li, Y.-Y., Liang, G.-D., Chen, Z.-X., Liu, S.-W., Yang, J.
  • Journal: Acta Pharmacologica Sinica, 2024

Isopeptide Bond Bundling Superhelix for Designing Antivirals against Enveloped Viruses with Class I Fusion Proteins: A Review

  • Authors: Na, H., Liang, G., Lai, W.
  • Journal: Current Pharmaceutical Biotechnology, 2023, 24(14), pp. 1774–1783

Hipponorterpenes A and B, two new 14-noreudesmane-type sesquiterpenoids from the juice of Hippophae rhamnoides

  • Authors: Zhang, X.-L., Na, H.-Y., Li, P.-S., Liang, G.-D., Hua, H.-M.
  • Journal: Phytochemistry Letters, 2022, 52, pp. 82–86

De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery

  • Authors: Wang, C., Zhao, L., Xia, S., Jiang, S., Liu, K.
  • Journal: Journal of Medicinal Chemistry, 2018, 61(19), pp. 8734–8745